Compare Ford Motor Company (F) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Ford Motor Company trades at $12.03 (market cap $48.25B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Ford Motor Company is far larger — about 49.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Ford Motor Company pays a 4.96% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 105 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| F | MRVI | |
|---|---|---|
Market Cap | $48.25B | $972.90M |
Volume | 33,627,673 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $9.00 |
52-Week Low | $11.21 | $2.83 |
Typical Hold Time | 105 Days | 0 Days |
Enterprise Value | $180.21B | $1.08B |
Dividend Yield | 4.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.05, up 0.42% on the day, with a mixed technical picture showing bearish moving averages but oversold RSI conditions. Fundamentally, the company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with negative profit margins and declining sales trends. Recent news highlights supplier disruptions affecting F-150 production and a 6.6% Q3 sales decline, though the company maintains its No. 3 U.S. market position.
Ford faces significant challenges with negative profitability and competitive pressures, though analyst consensus suggests 31% upside to the $15.79 price target. The stock presents a value opportunity given low P/S and P/B ratios, but investors must weigh operational headwinds against the company's strong commercial division and ongoing hybrid vehicle transition.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
